The Number of COVID-19 Tests Keeps Growing with New Hologic Diagnostic

Hologic said it has won Emergency Use Authorization for the Aptima SARS-CoV-2 test. This is the second EUA the Marlborough, MA-based company has received for a COVID-19 test.

Omar Ford

May 15, 2020

1 Min Read
MDDI logo in a gray background | MDDI

FDA is still granting Emergency Use Authorization (EUA) for COVID-19 tests, even though the conversation surrounding is shifting to antibody testing.

This time Hologic has received EUA for the Aptima SARS-CoV-2 test. The Marlborough, MA-based company received authorization for a COVID-19 detection tool in March.

The Aptima SARS-CoV-2 test runs on Hologic’s Panther system. The company said each Panther system can provide initial results in about three hours and process more than 1,000 coronavirus tests in 24 hours.

The test is being distributed and Hologic said it expects to produce an average of one million tests per week.“Delivering test results when and where they are needed – so people can either get back to work or quarantine themselves – is key to re-opening global economies safely,” Steve MacMillan, the company’s Chairman, president and CEO, said in a release. “I’m so proud of the incredible teamwork across the company that brought this test to market so quickly.”

Hologic said it plans to register its Aptima SARS-CoV-2 assay for a CE mark later this month.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like